Exicure (XCUR) 10-K2020 FY Annual report

Filed: 11 Mar 21, 5:26pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AAV, absolute, AEs, affirmative, Andrew, Angelman, antioxidant, Atalanta, ATM, avelumab, Avidity, back, Biden, blockade, BMO, CAA, California, Cavroltolimod, cavrotolimod, cemiplimab, cerebrospinal, chairperson, compartment, conventional, corroborated, CRO, CSCC, CSF, dehydrogenase, diagram, discretionary, disproportionate, distancing, distant, District, Dyne, economy, Elizabeth, elongation, emphasize, entertain, evidencing, exceeding, exhaust, exit, exploratory, family, FedEx, Feltner, franchise, furlough, fusion, Garofalo, headcount, heightened, heightening, home, hypotension, immunocompromised, impede, imprisonment, improperly, Instruction, isolated, job, Judge, Larimar, leiomyosarcoma, lending, Leriglitazone, LIBOR, lifting, likelihood, lowest, magnitude, midcap, Minoryx, mitochondial, mitochondria, mitochondrial, mitochondrion, motivating, municipal, NaN, NantKWest, nationwide, Neubase, neuropathic, Newborn, NOL, noninjected, Northern, Omaveloxolone, oncolytic, online, ORR, outbreak, oxidative, pandemic, PD, Pembro, pharmacokinetic, postal, PPAR, predominantly, PTC, quarantine, rapid, Reata, Recombinant, regular, reinstated, remanded, remote, reoccurrence, reopening, Replimune, respiration, retention, retirement, SAE, Sassine, saving, SDH, sequester, shrinkage, spread, St, staffing, stand, standby, strive, subsided, succinate, Sulat, Switching, synergistic, teleconference, temperature, thereon, tie, triterpenoid, Trust, truthful, unconstitutional, Uninjected, unpaid, upheld, upregulate, upregulation, Vatiquinone, vendor, virtual, virtually, visit, voluntarily, Walt, wellbeing, worsening

Removed: accredited, accumulate, afforded, AG, amortize, amortizing, antibody, antigen, Avenue, bacteria, BBA, binding, biopsy, Brodalumab, cap, caption, carrier, cascade, ceased, Century, Certified, chemically, chimeric, circumstance, clearing, closed, colorectal, comparison, complexing, concluding, conclusion, confer, configuration, confirming, consecutive, consisted, contrast, controller, converting, cut, dated, deeper, deny, detailed, dilute, discontinuation, disrupting, distracting, effecting, efficient, efficiently, eighteen, element, emerge, encapsulating, encouraged, engineered, enumerated, evading, exempt, expanding, experiment, externally, extracellular, FDAAA, fight, flowed, flux, formation, Germany, greatest, grew, helper, host, IL, illustrate, implantation, inducing, informed, inhibited, inhibiting, inhibition, inoculated, insensitive, interacting, interfering, intermediate, interrogated, intraperitoneally, invading, involuntary, Journal, keratinocyte, Kingdom, Lamon, language, leaving, lender, lesion, lt, lymphoma, mask, maximum, membership, Merck, merged, messenger, minimally, miRNA, mission, mix, mobilize, modifying, modulating, modulation, Mologen, monoclonal, naturally, nivolumab, occasionally, ordinarily, origin, outlined, palpable, pathogen, penny, posted, posting, prepay, prime, privately, promise, promulgate, prototype, proven, quotation, rationally, reclassify, reevaluate, referendum, registering, resistant, responding, restate, restored, RNA, RNAi, Roche, siRNA, slated, Snyder, Squibb, step, stimulate, stimulation, Street, Suite, survive, survived, synergize, synthesized, tangible, template, thirteen, threshold, TLR, traditional, translation, understand, undruggable, unregistered, unused, visible, Wall

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

XCUR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

SECTION 1350 CERTIFICATIONS*

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), David A. Giljohann, Ph. D., Chief Executive Officer and Interim Chief Financial Officer of Exicure, Inc. (the “Company”) hereby certifies that, to the best of his knowledge:

1. The Company’s Annual Report on Form 10-K for the year ended December 31, 2020, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 11, 2021



/s/ David A. Giljohann
David A. Giljohann, Ph.D.
President, Chief Executive Officer, and Interim Chief Financial Officer (Principal Executive Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer)


*			This certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.